RESPIVax™ 5 + PH-M, a convenient, single dose vaccine to protect cattle against viral and bacteria challenges associated with Bovine Respiratory Disease (BRD), is now available from Huvepharma.
“We are committed to continuing to expand the product choices available to the cattle industry and are excited to work with the stocker and feedlot sectors as they incorporate RESPIVax into their receiving protocols,” says Glen Wilkinson, president of Huvepharma US. Huvepharma is a global pharmaceutical company with a focus on developing, manufacturing, and marketing human and animal health products.
RESPIVax 5/Pulmo-Guard PH-M vaccine received USDA license and has been shown to be effective for the vaccination of healthy cattle five months of age or older. In field safety trials conducted at feedyards in Kansas, Oklahoma and Colorado and involving 638 steers and heifers 4 months of age and older, RESPIVax™ 5 + PH-M containing modified live Infectious Bovine Rhinotracheitis (IBR), Bovine Viral Diarrhea Virus (BVDV) Type 1a and 2, Parainfluenza (PI3), Bovine Respiratory Syncytial Virus (BRSV), and a killed Mannehimia haemolytica and Pasteurella multocida bacterin toxoid diluent was demonstrated to be safe for use in weaned, non-pregnant cattle under field conditions when administered subcutaneously.
Additionally, RESPIVax™ 3 + PH-M containing modified live Infectious Bovine Rhinotracheitis (IBR), Bovine Viral Diarrhea Virus (BVDV) Type 1a and 2, and a killed Mannehimia haemolytica and Pasteurella multocida bacterin toxoid diluent is available. Both RESPIVax vaccines should be administered subcutaneously in the side of the neck and followed by a second dose of Pulmo-Guard PH-M as a booster given 14 to 28 days after the first dose.
A privately-owned company headquartered in Sofia, Bulgaria, Huvepharma’s U.S. headquarters are located in Peachtree City, GA.
RESPIVax is a registered trademark of Huvepharma, Inc
